Last reviewed · How we verify
Radiolabeled EDG-5506 Suspension — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Radiolabeled EDG-5506 Suspension (Radiolabeled EDG-5506 Suspension) — Edgewise Therapeutics, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Radiolabeled EDG-5506 Suspension TARGET | Radiolabeled EDG-5506 Suspension | Edgewise Therapeutics, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Radiolabeled EDG-5506 Suspension CI watch — RSS
- Radiolabeled EDG-5506 Suspension CI watch — Atom
- Radiolabeled EDG-5506 Suspension CI watch — JSON
- Radiolabeled EDG-5506 Suspension alone — RSS
Cite this brief
Drug Landscape (2026). Radiolabeled EDG-5506 Suspension — Competitive Intelligence Brief. https://druglandscape.com/ci/radiolabeled-edg-5506-suspension. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab